Biocorrx Inc (PK:BICX)

Business Focus: Healthcare Facilities & Services

Apr 03, 2024 08:30 am ET
BioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to Treat Pain, Depression, and Schizophrenia
via NewMediaWire --  BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer of innovative treatment programs for substance use and related disorders, today announced that its subsidiary BioCorRx Pharmaceuticals Inc., a clinical-stage...
Apr 02, 2024 08:30 am ET
BioCorRx Reports Business Update for 2023
via NewMediaWire — BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for the year ended December 31, 2023, and reported...
Feb 28, 2024 10:49 am ET
BioCorRx Pharmaceuticals Inc. Awarded NIDA Grant of Approximately $11 million Over Three Years for Research on BICX104, a Naltrexone Implant in Combination with Bupropion for the Treatment of MUD
via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance use and related disorders, announced that its subsidiary BioCorRx Pharmaceuticals Inc. has been awarded a 3-year...
Feb 08, 2024 09:52 am ET
BioCorRx Pharmaceuticals Inc. Appoints Neuroscientist Dr. Kate DeVarney to the Board of Directors
via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, announced that its subsidiary BioCorRx Pharmaceuticals Inc., has appointed Kate...
Jan 09, 2024 08:30 am ET
BioCorRx Appoints Renowned Investment and Capital Markets Executive Louis Lucido as President
via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, announced the appointment of Louis Lucido as Interim President of the Company,...
Nov 14, 2023 12:52 pm ET
BioCorRx Reports Business Update for the Third Quarter of 2023
via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for the three months ended September 30, 2023, and...
Aug 15, 2023 09:00 am ET
BioCorRx Submits Expanded Access Treatment Protocol to FDA for BICX104, Implantable Biodegradable Naltrexone Pellet for Treatment of Opioid Use Disorder
via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”) today announced its submission to the US Food and Drug Administration (FDA) of an expanded access program application for BICX104 (implantable naltrexone pellet) for the treatment of...
Aug 14, 2023 04:34 pm ET
BioCorRx Reports Business Update for the Second Quarter of 2023
via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for the three months ended June 30, 2023, and...
Jul 18, 2023 08:30 am ET
BioCorRx Submits Fast Track Application to FDA for BICX104, an Implantable Biodegradable Naltrexone Pellet for The Treatment of Opioid Use Disorder
via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced the submission of a fast track application to the U.S. Food and...
May 16, 2023 08:30 am ET
BioCorRx Provides Business Update for the First Quarter of 2023
via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for the three months ended March 31, 2023 and...
Apr 03, 2023 08:30 am ET
BioCorRx Provides Business Update for 2022
via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for the year ended December 31, 2022 and reported...
Mar 07, 2023 03:13 pm ET
BioCorRx Announced Interim Positive Safety and Pharmacokinetic Results of Phase 1 Clinical Trial at 4th Annual NIH HEAL Initiative Investigator Meeting
via NewMediaWire – BioCorRx Inc. (OTCQB:  BICX) (the “Company”), a clinical-stage developer and provider of innovative treatment programs for substance use and related disorders, has announced interim positive safety and pharmacokinetic (PK)...
Feb 23, 2023 08:30 am ET
BioCorRx Attended 4th Annual NIH HEAL Initiative Investigator Meeting; Shares Update on BICX104 Data
via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance use and related disorders, announced today that Dr. Andrew Mallon, CSO and Grant Principal Investigator on the...
Jan 27, 2023 08:30 am ET
BioCorRx to Present at Sequire Biotechnology Conference on February 2nd
via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance use and related disorders, announced today that Lourdes Felix, Chief Executive Officer, Chief Financial...
Jan 24, 2023 09:00 am ET
BioCorRx Appoints Pharmaceutical & Finance Veteran Harsha Murthy to the Board of Directors
via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance use and related disorders, today announced that Mr. Harsha Murthy was appointed to the Company’s Board of...
Jan 19, 2023 08:30 am ET
BioCorRx Announces Completion of Treatment Phase of Study Subjects and Preliminary Safety Data from Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use
via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance use and related disorders, today announced an update from the Phase I clinical trial of BICX104, an implantable...
Jan 11, 2023 09:00 am ET
Avalon GloboCare Appoints Lourdes Felix, CEO of a Premier Addiction Treatment Company, to its Board of Directors
Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a leading global developer of innovative cell-based technologies and therapeutics and laboratory testing provider, today announced that it has appointed Lourdes Felix to its Board...
Dec 07, 2022 09:00 am ET
BioCorRx Partners with Government Plus to Expand its Beat Addiction Recovery Program in the United States
via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that it has partnered with Government Plus LLC, a leading provider...
Nov 22, 2022 09:00 am ET
BioCorRx Board of Directors Approves Exploration of Potential Spin-Off of BioCorRx Pharmaceuticals, Inc.
via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that its board of directors has authorized the exploration of a...
Nov 15, 2022 09:00 am ET
BioCorRx Provides Business Update for the Third Quarter of 2022
via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for the third quarter ended September 30, 2022...
Oct 24, 2022 11:30 am ET
BioCorRx to Present at the LD Micro Main Event XV on October 25th
Anaheim, California--(Newsfile Corp. - October 24, 2022) - BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that Lourdes Felix, Chief Executive Officer, Chief Financial Officer, and Director of BioCorRx Inc., and Brady Granier, President, Director of BioCorRx Inc. and CEO of BioCorRx Pharmaceuticals Inc., will be presenting at the 15th annual LD Micro Main Event being held on October 25 - 27, 2022 at the Luxe Sunset Boulevard Hotel in Los Angeles, California.
Oct 20, 2022 09:00 am ET
BioCorRx to Participate at the LD Micro Main Event XV
Anaheim, California--(Newsfile Corp. - October 20, 2022) - BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that Lourdes Felix, Chief Executive Officer, Chief Financial Officer, and Director of BioCorRx Inc., and Brady Granier, President, Director of BioCorRx Inc. and CEO of BioCorRx Pharmaceuticals Inc., will be participating at the 15th annual LD Micro Main Event being held on October 25 - 27, 2022 at the Luxe Sunset Boulevard Hotel in Los Angeles, California.
Oct 13, 2022 08:30 am ET
BioCorRx Completes Final Subject Enrollment in Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder
via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that the last subject has been enrolled in the Phase I clinical...
Sep 06, 2022 08:30 am ET
BioCorRx to Present at the H.C. Wainwright 24th Annual Global Investment Conference
via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that Lourdes Felix, CEO, CFO, and Director of BioCorRx, will be...
Aug 16, 2022 08:30 am ET
BioCorRx Provides Business Update for the Second Quarter of 2022
via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for the second quarter ended June 30, 2022 and...
Jul 13, 2022 08:30 am ET
BioCorRx to Participate in the Benzinga All Access Event on July 15th
via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that Brady Granier, President and Director of BioCorRx Inc. and CEO...
Jul 06, 2022 09:00 am ET
BioCorRX Inc. Discusses BICX104 Human Trials and 2B3D Metaverse Partnership with The Stock Day Podcast
Phoenix, Arizona--(Newsfile Corp. - July 6, 2022) - The Stock Day Podcast welcomed BioCorRx Inc. (OTCQB: BICX) ("the Company"), an addiction treatment solutions company offering a unique approach to the treatment of substance use and other related disorders. CEO and CFO of the Company, Lourdes Felix, joined Stock Day host Everett Jolly.
Jun 30, 2022 09:00 am ET
BioCorRx Announces First Subject Dosed in Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder
via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that the first subject has been dosed in the Phase I clinical...
Jun 17, 2022 09:00 am ET
BioCorRx Featured on LiveNOW from FOX
via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that Tom Welch, Executive Vice President of BioCorRx Inc., was...
May 31, 2022 09:00 am ET
BioCorRx to Present at the LD Micro Invitational XII on June 7th
via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that Lourdes Felix, Chief Executive Officer, Chief Financial...
May 19, 2022 08:00 am ET
BioCorRx and 2B3D to Pilot First-of-its-Kind PTSD and Addiction Treatment Solutions for Veterans in Metaverse Setting
via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that it is collaborating with 2B3D, a virtual, augmented, and mixed...
May 17, 2022 08:30 am ET
BioCorRx Business Update for the First Quarter of 2022
via NewMediaWire  – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for the first quarter ended March 31, 2022 and...
Apr 27, 2022 08:30 am ET
BioCorRx Begins Recruitment for Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder
via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that it has begun the recruiting and enrollment process for its...
Apr 26, 2022 08:30 am ET
BioCorRx to Present at the Planet MicroCap Showcase 2022 in Las Vegas on May 4th
ANAHEIM, CA / ACCESSWIRE / April 26, 2022 / BioCorRx Inc. (OTCQB:BICX) (the "Company"), a developer and provider of innovative treatment programs fr substance abuse and related disorders, today announced that it will present at the Planet MicroCap Showcase 2022 on Wednesday, May 4, 2022 at 3:00 PM Pacific Time/ 6:00 PM Eastern Time at the Bally's Hotel & Casino in Las Vegas, NV.
Apr 19, 2022 09:01 am ET
BioCorRX Inc. Discusses FDA Approval Process for Implantable Naltrexone Pellet, BICX104, with The Stock Day Podcast
Phoenix, Arizona--(Newsfile Corp. - April 19, 2022) - The Stock Day Podcast welcomed BioCorRx Inc. (OTCQB: BICX) ("the Company"), an addiction treatment solutions company offering a unique approach to the treatment of substance use and other related disorders. Director, CEO, and CFO of the Company, Lourdes Felix, joined Stock Day host Everett Jolly.
Apr 11, 2022 08:30 am ET
BioCorRx Announces Additional Award of Nearly $100,000 from NIDA for BICX104, its Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder
via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that it has been awarded a supplemental grant of approximately...
Apr 01, 2022 08:30 am ET
BioCorRx Provides 2021 Year-End Business Update
via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a year-end business update for 2021 and reported on recent...
Mar 22, 2022 08:30 am ET
BioCorRx to Participate in Two Upcoming Conferences
via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that management will be participating in two upcoming conferences....
Mar 16, 2022 09:00 am ET
BioCorRx Announces IRB Approval to Begin Phase I Clinical Trial of BICX104, an Implantable Biodegradable Naltrexone Pellet for the Treatment of Opioid Use Disorder
via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced it has received Independent Institutional Review Board (IRB)...
Mar 02, 2022 08:30 am ET
BioCorRx to Present at the Q1 Investor Summit Conference on March 9th
Anaheim, California--(Newsfile Corp. - March 2, 2022) - BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that management will present at the Q1 Investor Summit, hosted by the Investor Summit Group, being held virtually on March 8-9, 2022.
Feb 14, 2022 08:30 am ET
BioCorRx Announces Orange County Research Center as Clinical Trial Site for First-In-Human Clinical Trial of BICX104
via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, is pleased to announce that it has completed its clinical trial agreement with...
Jan 05, 2022 09:00 am ET
BioCorRx to Present at the H.C. Wainwright BioConnect 2022 Conference
via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that Lourdes Felix, CEO, CFO and Director of BioCorRx Inc.,...
Dec 09, 2021 09:00 am ET
BioCorRx Appoints Drug Delivery Expert Jie Shen, Ph.D., to Scientific Advisory Board
via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced the appointment of Dr. Jie Shen to the Scientific Advisory Board...
Nov 24, 2021 08:30 am ET
BioCorRx to Participate in the Benzinga All Access Event on December 2nd
via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that Lourdes Felix, CEO, CFO and Director of BioCorRx, Inc. and...
Nov 22, 2021 09:15 am ET
BioCorRx Acquires Intellectual Property for Drug Delivery
via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that the Company has acquired a patent application from Calista...
Nov 16, 2021 09:23 am ET
BioCorRx Provides Business Update for the Third Quarter of 2021
via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for the third quarter ended September 30, 2021...
Nov 10, 2021 02:47 pm ET
BioCorRx to Present at the Q4 Investor Summit Conference on November 16th
Anaheim, California--(Newsfile Corp. - November 10, 2021) - BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that management will present at the Q4 Investor Summit, hosted by the Investor Summit Group, being held virtually on November 16-17, 2021.
Oct 07, 2021 08:30 am ET
BioCorRx Files Patent Application with the Russian Patent Office (Rospatent) for Naltrexone Implant
via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, announced today that it has filed a patent application with the Russian Patent Office...
Sep 29, 2021 12:16 pm ET
BioCorRx to Present at LD Micro Main Event on Tuesday, October 12th
via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, announced today that it will be presenting at LD Micro’s 14th annual Main Event on Tuesday,...
Sep 22, 2021 08:30 am ET
BioCorRx Files Patent Application with USPTO for Naltrexone Implant
via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, announced today that it has filed a patent application with the U.S. Patent and Trademark...
Sep 08, 2021 07:00 am ET
Recro and BioCorRx Expand Development and Manufacturing Relationship to Support BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder
Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges in small molecule therapeutic development, and BioCorRx, Inc. (“BioCorRx”;...
Sep 08, 2021 07:00 am ET
Recro and BioCorRx Expand Development and Manufacturing Relationship to Support BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder
via NewMediaWire -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges in small molecule therapeutic development, and...
Sep 01, 2021 08:30 am ET
BioCorRx Announces Award of Approximately $3.5 Million NIDA Grant for the Clinical Trial of BICX104, its Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder
via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, announced today that it has been awarded approximately $3.5 million for the second phase of...
Aug 16, 2021 08:30 am ET
BioCorRx Provides Business Update for the Second Quarter of 2021
via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, today provided a business update for the second quarter ended June 30, 2021 and reported on...
Jun 22, 2021 08:30 am ET
BioCorRx Welcomes Four Experts to Expanded Scientific Advisory Board
via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (“BioCorRx” or the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, today announced the addition of Dr. Ashok Kumar MSc DIoD FRCPath, Michael...
May 18, 2021 09:04 am ET
BioCorRx Provides Business Update for the First Quarter of 2021
via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (“BioCorRx” or the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, today provided a business update for the first quarter ended March 31, 2021...
May 10, 2021 08:30 am ET
BioCorRx Receives FDA Clearance of Investigational New Drug (IND) Application for BICX104, its Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder
via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (“BioCorRx” or the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, announced today that the U.S. Food and Drug Administration (FDA) has given...
Apr 13, 2021 08:00 am ET
BioCorRx Announces Submission of IND Application to the FDA for BICX104, Implantable Naltrexone
via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (“BioCorRx” or the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, announced today that the Company has filed an Investigational New Drug (IND)...
Apr 01, 2021 08:30 am ET
BioCorRx Provides 2020 Year-End Business Update
via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, today provided a year-end business update for 2020 and reported on recent corporate...
Mar 02, 2021 09:24 am ET
BioCorRx Completes $2.25 Million Private Placement
via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, today announced that the Company completed a private placement, whereby it issued 1.125...
Feb 24, 2021 08:30 am ET
BioCorRx Appoints Finance Veteran Joseph J. Galligan to the Board of Directors
via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, today announced that Joseph J. Galligan was appointed to the Company’s Board of Directors....
Jan 15, 2021 08:30 am ET
BioCorRx Announces Update on NIDA Grant and Development of Naltrexone Implant for the Treatment of Opioid and Alcohol Use Disorders
via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, today announced that it has received a revised notice of award (NoA) to extend the current...
Nov 16, 2020 08:30 am ET
BioCorRx Provides Business Update for the Third Quarter of 2020; BioCorRx Subsidiary, BioCorRx Pharmaceuticals Inc. Progressing with Pivotal Nonclinical BICX102 Study
via NewMediaWire ‒ BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, today provided a business update for the third quarter ended September 30, 2020. The Company...
Oct 13, 2020 08:30 am ET
BioCorRx Partners with Truusight Health to Integrate Recovery Program Into Self-Funded Health Plans
via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (“BioCorRx®”) (“Company”), a developer and provider of advanced solutions in the treatment of substance use disorders (SUD), today announced their partnership with Truusight Health, a healthcare...
Aug 14, 2020 08:30 am ET
BioCorRx Provides Business Update for the Second Quarter of 2020
via NEWMEDIAWIRE -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, today provided a business update for the second quarter ended June 30, 2020.  Brady...
May 22, 2020 08:30 am ET
BioCorRx Provides Update on Current Business Operations and on GLP Studies of BICX102; Uninterrupted by COVID-19 Pandemic
via NEWMEDIAWIRE -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, today provided a business update and reported on recent corporate developments. Brady...
Apr 10, 2020 08:30 am ET
BioCorRx Offers Free Access to the UnCraveRx™ Mobile Platform for Weight Loss Management During COVID-19 Pandemic
via NEWMEDIAWIRE -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, today announced that it is offering free access to the UnCraveRx™ App for a limited time....
Apr 07, 2020 10:24 am ET
BioCorRx Offers Free Access to the BioCorRx Recovery Program Mobile Platform for Medical Professionals During COVID-19 Pandemic
via NEWMEDIAWIRE -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, today announced that it is offering substance use disorder (SUD) medical professionals free...
Mar 31, 2020 08:30 am ET
BioCorRx Provides Business Update; Pivotal GLP Study of BICX102 Uninterrupted by COVID-19 Pandemic
via NEWMEDIAWIRE -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, today provided a business update and reported on recent corporate developments. Brady...
Mar 02, 2020 09:26 am ET
BioCorRx Announces Senior Management Promotions
via NEWMEDIAWIRE -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use and related disorders to help save lives and improve health, today announced the promotions of Lourdes...
Jan 30, 2020 09:32 am ET
BioCorRx Announces Award of $2.8 Million, the Second Tranche of a NIDA Grant for the Development of BICX102, a Sustained Release Naltrexone Implant for the Treatment of Opioid Use Disorder
via NEWMEDIAWIRE --BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, has been awarded an additional $2.8 million. This is the second tranche from the total grant...
Dec 19, 2019 08:30 am ET
BioCorRx Provides 2019 Year-End Business Update
via NEWMEDIAWIRE --BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, today provided a year-end business update for 2019 and reported on recent corporate...
Dec 03, 2019 08:30 am ET
BioCorRx’s Subsidiary, BioCorRx Pharmaceuticals Provides Update on Potential Overdose Reversal Drug Candidate VDM-001
via NEWMEDIAWIRE -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a leader, developer and provider of advanced solutions in the treatment of addiction and related disorders, today provided an update on VDM-001, a new opioid antagonist being...
Oct 30, 2019 08:30 am ET
BioCorRx Announces UnCraveRx™ a Medically-Assisted Weight Loss Program as Sponsor and Exhibitor at the 36th Annual American Society of Metabolic and Bariatric Society Meeting
via NEWMEDIAWIRE -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a leader, developer and provider of advanced solutions in the treatment of addiction and related disorders, today announces its medically-assisted weight loss program, UnCraveRx™, as...
Oct 22, 2019 08:15 am ET
BioCorRX Discusses UnCraveRX Launch with The Stock Day Podcast
Phoenix, Arizona--(Newsfile Corp. - October 22, 2019) - The Stock Day Podcast welcomed BioCorRX (OTCQB: BICX) ("the Company"), an addiction treatment solutions company offering a unique approach to the treatment of substance use and other related disorders. CFO and COO of the Company, Lourdes Felix, joined Stock Day host Everett Jolly.
Oct 08, 2019 08:30 am ET
BioCorRx Announces the Official Launch of UnCraveRx, a Medically-Assisted Weight Loss Management Program
via NEWMEDIAWIRE -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a leader, developer and provider of advanced solutions in the treatment of addiction and related disorders, today announced that it has launched its UnCraveRx™, a medically-assisted...
Oct 07, 2019 08:30 am ET
BioCorRx Announces Capital Restructuring and Provides Business Update
via NEWMEDIAWIRE – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, today provided a business update and reported progress on the development of BICX102, the...
Jul 30, 2019 08:30 am ET
BioCorRx Joins the Stock Day Podcast to Discuss Their Growing Treatment and Weight Loss Programs
PHOENIX, AZ / ACCESSWIRE / July 30, 2019 / The Stock Day Podcast welcomed BioCorRx (OTCQB:BICX) (“the Company”), an addiction treatment solutions company offering a unique approach to the treatment of substance use and other related disorders. COO and CFO, Lourdes Felix, joined Stock Day host Everett Jolly.
Jul 29, 2019 07:55 am ET
Lourdes Felix, Chief Operating Officer and Chief Financial Officer of BioCorRx Inc. Discusses the Launch of the UnCraveRx™ Virtual App in a New Interview at SmallCapVoice.com
BioCorRx Inc. (OTC QB: BICX) (the “Company”), a leader, developer and provider of advanced solutions in the treatment of addiction and related disorders, today announced that Lourdes Felix, CFO, COO and Director of BioCorRx Inc. is featured in a...
Jul 22, 2019 02:03 pm ET
BioCorRx’s Director Louis Lucido Appeared Today on Yahoo Finance LIVE “On the Move”
via NEWMEDIAWIRE -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a leader, developer and provider of advanced solutions in the treatment of addiction and related disorders, today announced that the Company’s Director Louis Lucido appeared as a...
Jul 22, 2019 08:30 am ET
BioCorRx Announces the Launch of UnCraveRx On-Demand Virtual Fitness, Lifestyle Support and Nutrition App
via NEWMEDIAWIRE -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a leader, developer and provider of advanced solutions in the treatment of addiction and related disorders, today announced that it has launched the UnCraveRx™ virtual app. UnCraveRx™...
May 02, 2019 08:00 am ET
BioCorRx, Inc. Announces Launch of Pilot Program with Louisiana Department of Corrections for Offenders Suffering with Alcohol and Opioid Use Disorders
via NEWMEDIAWIRE -- BioCorRx Inc. (OTCQB: BICX) (“BioCorRx®”)(“Company”), a leader, developer and provider of advanced solutions in the treatment of addiction and related disorders, today announces treatment of the first patient in its partnership...
May 01, 2019 08:30 am ET
BioCorRx Inc. Unveils New UnCraveRx™ Weight Loss Program; Appoints Notable Dr. Kenneth Orbeck as Medical Director
via NEWMEDIAWIRE – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a leader, developer and provider of advanced solutions in the treatment of addiction and related disorders, today announced that it has unveiled its new UnCraveRx™ Weight Loss Program...
Apr 30, 2019 09:50 am ET
BioCorRx to Present at the Planet MicroCap Showcase 2019 on May 1st in Las Vegas
via NEWMEDIAWIRE -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a leader, developer and provider of advanced solutions in the treatment of addiction and related disorders, today announced it will present at the Planet MicroCap Showcase at 4:00...
Apr 10, 2019 08:30 am ET
Uptick Newswire Hosts BioCorRx Inc. on the Stock Day Podcast to Discuss Major Company Updates
PHOENIX, AZ / ACCESSWIRE / April 10, 2019 / Uptick Newswire Stock Day Podcast welcomed BioCorRx Inc. (OTCQB: BICX) ("the Company"), an addiction treatment solutions company offering a unique approach to the treatment of alcohol and opioid use disorders. President and CEO, Brady Granier, joined Stock Day host Everett Jolly.
Apr 04, 2019 07:30 am ET
Joseph J. Galligan Appointed as Senior Advisor to BioCorRx Inc.
via NEWMEDIAWIRE -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a leader, developer and provider of advanced solutions in the treatment of addiction and related disorders, today announced that Joseph J. Galligan has been appointed as senior...
Apr 02, 2019 07:30 am ET
BioCorRx Announces Above Market $6 Million Private Placement at $15 Per Share
via NEWMEDIAWIRE -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a leader, developer and provider of advanced solutions in the treatment of addiction and related disorders, today announced the Company completed a private placement, whereby it...
Mar 28, 2019 08:00 am ET
BioCorRx’s Subsidiary, BioCorRx Pharmaceuticals, to Exhibit at ASAM 50th Annual Conference in Orlando, Florida
via NEWMEDIAWIRE -- BioCorRx Inc. (OTCQB: BICX) (the “Company), a developer and provider of advanced solutions in the treatment of substance abuse disorders, today announced that the Company’s subsidiary, BioCorRx Pharmaceuticals, will exhibit at...
Mar 27, 2019 07:37 am ET
BioCorRx Promotes Dr. Balbir S. Brar to Senior VP of Drug Development; Extends Service Agreement
via NEWMEDIAWIRE -- BioCorRx Inc. (OTC: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of substance abuse disorders, today announced that it has promoted Dr. Balbir S. Brar to Senior VP of Drug Development...
Mar 14, 2019 08:00 am ET
BioCorRx to Present at the 31st Annual ROTH Conference on March 17-19, 2019
via NEWMEDIAWIRE -- BioCorRx Inc. (OTCQB: BICX) (“Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, announced today that the Company has been invited to present at the 31st Annual ROTH Conference...
Feb 26, 2019 08:00 am ET
BioCorRx Partners with IRISYS for Manufacturing of BICX102 Naltrexone Implant for Treatment of Opioid Use Disorder
via NEWMEDIAWIRE -- BioCorRx Inc. (OTCQB: BICX) (“Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, announced today that it has engaged IRISYS, LLC, a contract pharmaceutical product development...
Feb 25, 2019 08:00 am ET
BioCorRx Appoints Two Finance Veterans to the Board of Directors
via NEWMEDIAWIRE – BioCorRx Inc. (OTCQB: BICX) (“Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, announced today the addition of two new independent directors, Louis Lucido and Luisa...
Feb 25, 2019 06:00 am ET
February 20th Virtual Investor Conferences Company Investor Presentations Now Available for On-Demand Viewing
NEW YORK, Feb. 25, 2019 /PRNewswire/ -- Virtual Investor Conferences, the leading proprietary investor conference series, announced that the presentations from the February 20th, 2019 conference are now available for on-demand viewing at VirtualInvestorConferences.com.
Feb 19, 2019 10:26 am ET
BioCorRx Announces Formation of Scientific Advisory Board
via NEWMEDIAWIRE -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, announced today the formation of its Scientific Advisory Board (SAB) with three key...
Feb 15, 2019 03:01 pm ET
Live Investor Conference & Webinar February 20th
NEW YORK, Feb. 15, 2019 /PRNewswire/ -- Virtual Investor Conferences today announced the agenda for the upcoming Virtual lnvestor Conference, the leading proprietary investor conference series.  Individual investors, institutional investors, advisors and analysts are invited to attend. The program opens at 9:00 AM ET, with the first live webcast at 9:15 AM ET, on Wednesday, February 20th.
Feb 15, 2019 07:35 am ET
BioCorRx Inc. to Webcast Live at VirtualInvestorConferences.com February 20th
ANAHEIM, Calif., Feb. 15, 2019 /PRNewswire/ -- BioCorRx Inc. (BICX), based in Anaheim, CA, Leader in addiction treatment solutions and drug development implementation, today announced that Brady Granier, CEO/President and Lourdes Felix, CFO/COO, will present live at VirtualInvestorConferences.com on February 20th.
Jan 28, 2019 09:00 am ET
Uptick Newswire Hosts BioCorRx Inc’s CEO and CFO to Discuss Their Recent NIDA Grant for Their Naltrexone Implant for Opioid Use Disorder
The Uptick Newswire Stock Day Podcast welcomed BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions. President, CEO, and Director of BioCorRx Inc Brady Granier...
Jan 23, 2019 08:00 am ET
BioCorRx Announces Reverse Stock Split in Preparation for Proposed Uplisting to NASDAQ Capital Market
via NEWMEDIAWIRE -- BioCorRx Inc. (OTCQB: BICX; BICXD) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, announced today a reverse stock split of its shares of common stock at a ratio of...
Jan 22, 2019 07:30 am ET
BioCorRx Awarded NIDA Grant of Approximately $5.7 Million for BICX102, a Sustained Release Naltrexone Implant for the Treatment of Opioid Use Disorder
via NEWMEDIAWIRE – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, announced today that it has been awarded a 2-year grant from the National Institute on Drug...
Dec 12, 2018 08:00 am ET
Brady Granier, CEO, President, and Director of BioCorRx Inc. Provides Update and Outlook in a New Audio Interview with SmallCapVoice.com
SmallCapVoice.com, Inc. (SCV) and BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of substance use disorders, announced today that a new audio interview with the Company is now available....
Nov 14, 2018 08:00 am ET
BioCorRx Provides Business Update for the Third Quarter of 2018
via NEWMEDIAWIRE – BioCorRx, Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, today provided a business update for the third quarter ended September 30, 2018. Brady...
Oct 23, 2018 09:47 am ET
BioCorRx Inc.’s CEO Talks NIDA Grant Update and a Promising New Product with Uptick Newswire’s Stock Day Podcast
BioCorRx Inc. (OTCQB: BICX) (the "Company") is a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions. President, CEO, and Director of BioCorRx Inc, Brady Granier talked with Stock Day’s Everett Jolly about...
Oct 19, 2018 07:30 am ET
BioCorRx Strengthens Intellectual Property Portfolio with Acquisition of Several Patent/Patent Pending Families
via NEWMEDIAWIRE -- BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced that the Company’s R subsidiary, BioCorRx Pharmaceuticals, has...
Oct 09, 2018 08:00 am ET
BioCorRx, Inc. Announces Preliminary Agreement with VDM Biochemicals to Develop and Commercialize Patented Opioid Antagonist VDM-001
VDM-001 represents potential alternative to naloxone for overdose reversal; Potential to reduce cravings from substance use disorder  via NEWMEDIAWIRE -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced...
Oct 05, 2018 07:30 am ET
BioCorRx to Exhibit at the International Association of Chiefs of Police 2018 Annual Conference in Orlando, Florida
via NEWMEDIAWIRE – BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced that the Company will have an exhibit at the International Association...
Oct 02, 2018 07:51 am ET
BioCorRx Provides BICX102 Grant Update
via NEWMEDIAWIRE -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, today provided an update on the grant submitted to The National Institute on Drug Abuse...
Sep 25, 2018 11:11 am ET
BioCorRx CEO Brady Granier Discusses BioCorRx Recovery Program on This Life #YouLive Podcast Hosted by Dr. Drew
via NEWMEDIAWIRE-- BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced that Brady Granier, BioCorRx CEO, President, and Director, appeared as...
Sep 20, 2018 09:24 am ET
BioCorRx to Exhibit at the 2nd Annual National Opioid Crisis Management Congress
via NEWMEDIAWIRE -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced that the Company will host an exhibit at the 2nd Annual National...
Sep 12, 2018 07:43 am ET
Actor Jeremy Miller Appears on Local ABC News Supporting BioCorRx Recovery Program
via NEWMEDIAWIRE -- BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced that actor Jeremy Miller appeared on Omaha, Nebraska’s local news...
Aug 15, 2018 08:00 am ET
BioCorRx Provides Business Update for the Second Quarter of 2018
BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, today provided a business update for the second quarter ended June 30, 2018. Second Quarter 2018 Business...
Aug 07, 2018 07:30 am ET
BioCorRx Provides Update on BICX102
BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced a general update on BICX102, the Company’s sustained release naltrexone implant for the...
Jul 24, 2018 08:00 am ET
Brady Grainer, CEO of BioCorRX Inc. Joins Everett Jolly on “Stock Day”
Uptick Newswire, today announced the return of BradyGrainer, CEO of BioCorRX Inc. to Uptick Newswire’s Stock Day podcast with Everett Jolly. The Company is a developer and provider of advanced solutions in the treatment of alcohol and opioid...
Jun 06, 2018 07:00 am ET
BioCorRx Raises $1.1 Million at Premium to Market
BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced the Company recently sold 5.5 million shares of common stock in a private placement at a...
May 22, 2018 07:30 am ET
BioCorRx Announces Grant Submission to the National Institutes of Health for BICX102
BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced it has submitted a grant application to the National Institutes of Health (NIH) to fund...
May 21, 2018 07:30 am ET
BioCorRx Provides Business Update for the First Quarter of 2018
BioCorRx, Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, today provided a business update for the first quarter ended March 31, 2018. First Quarter 2018 Business...
Apr 30, 2018 07:00 am ET
BioCorRx Gains Additional Media Coverage from Fox Medical Correspondent Who Discusses the Advantages of the Naltrexone Implant
ANAHEIM, CA, April 30, 2018 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today reported that Dr. Mark Siegel, commented on the advantages of sustained...
Apr 26, 2018 08:47 am ET
BioCorRx CEO Brady Granier and Actor Jeremy Miller Appear on Varney & Co. on Fox Business to Discuss the Company's Sustained Release Naltrexone Implant for Alcohol Use Disorder
ANAHEIM, CA, April 26, 2018 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced that Brady Granier, BioCorRx CEO, President, and Director, as well as...
Apr 13, 2018 07:19 am ET
BioCorRx to Participate in the First Annual Orange County Recovery Collaborative Resource Fair
ANAHEIM, CA, April 13, 2018 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the “Company), a developer and provider of advanced solutions in the treatment of alcohol and opioid addition, today announced that the Company will participate in the...
Apr 10, 2018 07:30 am ET
BioCorRx to Exhibit at ASAM 49th Annual Conference in San Diego, California
ANAHEIM, CA, April 10, 2018 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the “Company), a developer and provider of advanced solution in the treatment of alcohol and opioid addition, today announced that the Company will have a tabletop...
Apr 09, 2018 12:25 pm ET
BioCorRx CEO Brady Granier and Legendary Soul Man Sam Moore Appear on Fox Business Network to Discuss the Company's Naltrexone Implant, Which Helps Combat Opioid Addiction
ANAHEIM, CA, April 09, 2018 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced that Brady Granier, BioCorRx CEO, President, and Director, and legendary...
Apr 06, 2018 07:30 am ET
BioCorRx Provides Business Update for the Full Year Ended 2017
ANAHEIM, CA, April 06, 2018 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today provided a business update for the year ended December 31, 2017.
Apr 05, 2018 07:30 am ET
BioCorRx Partner, Virtual Reality Medical Center, Submits Small Business Innovation Grant Application to the National Institute of Health
ANAHEIM, CA, April 05, 2018 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced that its partner, Virtual Reality Medical Center...
Mar 20, 2018 10:40 am ET
Mar 15, 2018 08:08 am ET
BioCorRx Provides Update on New Weight Management Program
ANAHEIM, CA, March 15, 2018 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced an update on the pilot program for...
Mar 06, 2018 07:30 am ET
BioCorRx to Exhibit at the Addiction Executives Industry Summit in Ponte Verde Beach, FL
ANAHEIM, CA, March 06, 2018 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced that the Company is currently exhibiting at...
Mar 01, 2018 07:30 am ET
BioCorRx Schedules Business Update Conference Call
ANAHEIM, CA, March 01, 2018 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced it will host a conference call on Thursday, March 8th...
Feb 15, 2018 08:00 am ET
Dr. Joseph DeSanto and BioCorRx Recovery Program Participant Appear on the TV Show, The Doctors
ANAHEIM, CA, Feb. 15, 2018 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced that Dr. Joseph DeSanto, founder of the DeSanto Clinics and provider...
Feb 08, 2018 07:30 am ET
BioCorRx Extends Service Agreement with Dr. Balbir S. Brar as VP of Drug Development Following Pre-IND Meeting with the U.S. FDA
ANAHEIM, CA, Feb. 08, 2018 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTC: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced that following the pre-Investigational New Drug (pre-IND) meeting with the...
Jan 26, 2018 07:30 am ET
BioCorRx Completes Pre-IND Meeting with FDA; Reports Company to Move Forward with BICX102
ANAHEIM, CA , Jan. 26, 2018 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced that it held a pre-Investigational New Drug (pre-IND) meeting...
Jan 24, 2018 07:30 am ET
BioCorRx Announces Collaboration with the One Day at a Time Program in Philadelphia
ANAHEIM, Calif., Jan. 24, 2018 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced a pilot for the BioCorRx® Recovery Program in collaboration with...
Jan 22, 2018 10:54 am ET
CORRECTION: CEO, Brady Granier, From BioCorRx® Inc. Discusses Upcoming FDA Meeting on “Stock Day” Podcast; Aims to Fight Opioid Crisis
CORRECTION: The text below more accurately reflects the audio interview content released January 22nd 2018 and the Company's products and services
Jan 22, 2018 07:00 am ET
CEO, Brady Grainer, From BioCorRx®Inc. Paves Pathway Towards Possible FDA Approval on “Stock Day” Podcast; Aims to Fight Opioid Crisis
PHOENIX, Jan. 22, 2018 (GLOBE NEWSWIRE) -- The Uptick Newswire “Stock Day” podcast keeps investors up to date on the latest penny stock news by bringing transparency in the micro-cap side of the market. Connect with “Stock Day”...
Jan 05, 2018 11:40 am ET
BioCorRx Retains Regulatory Drug Expert Priya Jambhekar and CMC Expert Bruce Firestone, Ph.D
ANAHEIM, CA, Jan. 05, 2018 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced that it has retained regulatory drug experts Priya Jambhekar and...
Jan 02, 2018 07:30 am ET
BioCorRx CEO, Brady Granier, Appears on Fox & Friends to Discuss the Opioid Epidemic
ANAHEIM, CA, Jan. 02, 2018 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced that Brady Granier, BioCorRx CEO, President, and Director, appeared as...
Dec 22, 2017 09:41 am ET
BioCorRx Recovery Program Used in Lieu of Conviction in Ohio
ANAHEIM, CA, Dec. 22, 2017 (GLOBE NEWSWIRE) --
Dec 19, 2017 07:30 am ET
BioCorRx Submits Pre-IND Package to FDA for its Naltrexone Implant, BICX102
ANAHEIM, CA, Dec. 19, 2017 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced that it has submitted its pre-Investigational New...
Dec 14, 2017 11:23 am ET
BioCorRx Enters Agreement with National Institute on Alcohol Abuse and Alcoholism
ANAHEIM, CA, Dec. 14, 2017 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of alcohol and opioid addiction, today announced that it has entered into an agreement...
Dec 12, 2017 12:17 pm ET
UPDATE: BioCorRx Announces Distribution Deal with CereCare, LLC for the BioCorRx Recovery Program
ANAHEIM, CA , Dec. 12, 2017 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of alcohol and opioid addiction, today announced that CereCare, LLC, a company focused...
Dec 12, 2017 10:29 am ET
Dec 12, 2017 07:30 am ET
BioCorRx Announces Distribution Deal with CereCare, LLC for the BioCorRx Recovery
ANAHEIM, CA, Dec. 12, 2017 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of alcohol and opioid addiction, today announced that CereCare, LLC, a company focused on...
Nov 16, 2017 08:00 am ET
BioCorRx Provides Business Update for the Third Quarter of 2017
BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of substance use disorders, today provided a business update for the third quarter ended September 30, 2017.
Nov 15, 2017 07:30 am ET
BioCorRx Enters Confidentiality Agreement with Federal Government Research Institute; Plans to Attend FDA Meeting for Naltrexone Implant
BioCorRx, Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addiction, today announced that it has entered into a confidentiality agreement with the National Institute on Drug Abuse (NIDA), a United States federal-government research institute whose mission is "to advance science on the causes and consequences of drug use and addiction and to apply that knowledge to improve individual and public health." The purpose of the agreement is to share confidential information and potentially collaborate on further research,
Oct 25, 2017 07:30 am ET
BioCorRx Announces Nine Centers to Implement BioCorRx Recovery Program Across Maryland and Virginia
BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced that Advanced Spine and Pain (ASAP) will implement the BioCorRx® Recovery Program in all nine of its locations in the Maryland and Virginia area. ASAP is the latest group of centers to implement the BioCorRx® Recovery Program, a non-addictive, medication-assisted treatment (MAT) program. The program combines the use of a patient specific naltrexone implant with a proprietary cognitive behavioral therapy (CBT) program
Oct 19, 2017 07:30 am ET
BioCorRx to Exhibit at the International Association of Chiefs of Police 2017 Annual Conference in Philadelphia
BioCorRx, Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced that the Company will have an exhibit at the International Association of Chiefs of Police (IACP) 2017 Annual Conference at the Pennsylvania Convention Center in Philadelphia, Pennsylvania on October 21-24th.
Oct 17, 2017 07:00 am ET
BioCorRx CEO Brady Granier Appears on MichaeLA on HLN to Discuss Alcohol Addiction
BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced that Brady Granier, President & CEO of BioCorRx, appeared as a guest on MichaeLA hosted by Michaela Pereira live from CNN's Los Angeles bureau, to discuss alcohol addiction and the BioCorRx® Recovery Program, which works to help people suffering from alcohol and opioid abuse disorders. The segment can be viewed in the News & Media section of the BioCorRx website. To find out more information on the BioCorRx Recovery Program
Oct 05, 2017 07:00 am ET
BioCorRx To Launch New Weight Management Program
BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced that the Company will begin a pilot program for weight-loss with Atlantis Medical Wellness & Weight Loss Center in Silver Spring, MD. The pilot program is expected to start on October 4, 2017. The Company expects to announce the name of its weight-loss program upon anticipated successful completion of the pilot program in Q4 2017.
Sep 12, 2017 09:38 am ET
BioCorRx Announces Beta Launch of Mobile Application for Opioid and Alcohol Substance Use Disorder
BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of substance use disorders, today announced the completion and beta launch of its proprietary mobile application for use by licensed behavioral specialists and individuals in treatment for opioid and alcohol use disorders. The application is scheduled to be made available in the Apple App Store and Google Play September 21, 2017.
Mar 27, 2017 08:00 am ET
Brady Granier, CEO, President, and Director and Lourdes Felix, CFO, COO and Director of BioCorRx Inc. Provide Updates and Outlook in a New Audio Interview with SmallCapVoice.com
AUSTIN, Texas, March 27, 2017 (GLOBE NEWSWIRE) -- SmallCapVoice.com, Inc. (SCV) and BioCorRx Inc. (OTCQB:BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, announced today that a new audio interview with the Company is now available. The interview can be heard at http://smallcapvoice.com/blog/3-24-17-smallcapvoice-interview-with-biocorrx-inc-bicx....
Jan 12, 2017 07:30 am ET
BioCorRx Retains Innovative Science Solutions to Guide FDA Regulatory Process for its Naltrexone Products
BioCorRx Inc. (OTC PINK: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced it has retained Innovative Science Solutions, LLC, ("ISS") a leading scientific consulting firm, headquartered in Morristown, New Jersey to help guide the Company's regulatory strategy for the submission of its sustained release naltrexone product(s) to the U.S. Food and Drug Administration (FDA). The company's injectable naltrexone product, BICX101 is being developed under its BioCorRx Pharmaceuticals subsidiary in partnership with
Oct 06, 2016 08:00 am ET
BioCorRx Inc. to Host Corporate Update Webinar on Wednesday, October 12th at 2:00 p.m. Eastern Time
BioCorRx Inc. (OTC PINK: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, announced today it will host a virtual webinar at 2:00 p.m. Eastern time (11:00 a.m. Pacific time) on Wednesday, October 12, 2016.
Sep 19, 2016 04:39 pm ET
BioCorRx Inc. to Present at the Singular Research 11th Annual Best of the Uncovereds Investment Conference September 22nd
BioCorRx Inc. (OTC PINK: BICX) (the "Company"), developer of the BioCorRx® Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, today announced that Brady Granier, CEO, and Lourdes Felix, CFO/COO, will present at the Singular Research 11th Annual Best of the Uncovereds Investment Conference on September 22, 2016 in Los Angeles.
Sep 15, 2016 08:00 am ET
BioCorRx Inc. Announces Update From First Joint Steering Committee Meeting for Injectable Naltrexone Product
BioCorRx Inc. (OTC PINK: BICX) (the "Company"), developer of the BioCorRx® Recovery Program, a medication-assisted treatment (MAT) program, announced today the update from the first joint steering committee (JSC) meeting in regards to the injectable naltrexone product the Company is developing in partnership with TheraKine Ltd. The Company previously announced its agreement with TheraKine for exclusive worldwide rights, licenses and sublicensing to patented and patent pending TheraKine technology for sustained release naltrexone delivery, as well as the assembling of an expert team to
Aug 31, 2016 12:34 pm ET
BioCorRx Inc. Announces BioCorRx Pharmaceuticals Subsidiary; Forms Joint Steering Committee for Injectable Naltrexone Technology
BioCorRx Inc. (OTC PINK: BICX) (the "Company"), developer of the BioCorRx® Recovery Program, a medication-assisted treatment (MAT) program, announced today the formation of a new subsidiary, BioCorRx Pharmaceuticals, in conjunction with the company's Development, Commercialization and License Agreement with TheraKine Ltd. for exclusive worldwide rights, licenses and sublicensing to patented and patent pending TheraKine technology for sustained release naltrexone delivery.
Aug 17, 2016 08:00 am ET
BioCorRx, Inc. Announces Agreement With Dr. David Gastfriend to Provide Strategic Initiative and Corporate Development Consulting
BioCorRx, Inc. (OTC PINK: BICX), developer of the BioCorRx® Recovery Program, a Medication-Assisted Treatment (MAT) program, announces a consulting and advisory agreement with David R. Gastfriend, M.D. The agreement with Dr. Gastfriend is part of the Company's continued drive to expand core business development capabilities and regulatory support infrastructure. Dr. Gastfriend will facilitate potential strategic directions and partnerships as well as provide situation specific expertise to the Company with regard to regulatory approval processes.
Aug 03, 2016 01:29 pm ET
BioCorRx Announces License Agreement With TheraKine Ltd. to Develop New Injectable Naltrexone Technology
BioCorRx Inc. (OTC PINK: BICX) (the "Company"), developer of the BioCorRx® Recovery Program, a non-addictive, medication-assisted treatment (MAT) program used in the treatment of alcohol and opioid addiction, announced today it has signed a Development, Commercialization and License Agreement with TheraKine Ltd. effective July 28, 2016 for exclusive worldwide rights, licenses and sublicensing to patented and patent pending TheraKine technology for sustained release medication delivery. The agreement is specific to the use of the technology to treat addictions using the medication,
Jul 20, 2016 10:28 am ET
BioCorRx Retains MZ Group as Investor Relations Advisor
BioCorRx Inc. (OTC PINK: BICX) (the "Company"), developer of the BioCorRx® Recovery Program, a non-addictive, medication-assisted treatment (MAT) program used in the treatment of alcohol and opioid addiction, announced today the Company has retained MZ Group as its investor relations advisor.
Jul 14, 2016 08:00 am ET
BioCorRx Launches R&D Initiative to Pursue FDA Approval for Naltrexone Implant
BioCorRx Inc. (OTCQB: BICX), developer of the BioCorRx® Recovery Program, a non-addictive medication-assisted treatment (MAT) program used in the treatment of alcohol and opioid addiction, announced today it is establishing a Research and Development initiative in order to seek U.S. Food and Drug Administration (FDA) approval for its naltrexone implant.
Jun 20, 2016 02:01 pm ET
Alpine Creek and BioCorRx Announce Major Investment Into BioCorRx
Alpine Creek Capital Partners ("Alpine Creek") and BioCorRx, Inc. (OTC PINK: BICX) ("BioCorRx" or "the Company") are pleased to announce an investment by Alpine Creek in the Company. The Company specializes in solutions for alcohol and opioid addiction treatment using its proprietary, non-addictive medication-assisted treatment (MAT) program called the BioCorRx® Recovery Program. The Company has the worldwide rights (except in Australia and New Zealand) to a highly effective, proprietary implant formulation of an FDA-approved medicine, naltrexone. After being surgically implanted by a
Apr 04, 2016 09:24 am ET
BioCorRx's Program to Help Beat Alcohol and Opioid Addiction Now in 20 Locations and Growing in Time for Alcohol Awareness Month
ANAHEIM, Calif., April 4, 2016 /PRNewswire-iReach/ -- Early April symbolizes the start of Alcohol Awareness Month, and BioCorRx®, a pioneer in the field of addiction treatment, is announcing that its comprehensive recovery program is now available at 20 independent locations nationwide with more coming soon. The outpatient, non-addictive, medication assisted treatment (MAT) program, is a cutting edge private treatment protocol that can give those suffering from addiction another opportunity to defeat their bondage to alcohol or opioids. The BioCorRx® Recovery Program begins by tackling the c

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.